Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Ambros Therapeutics | Werewolf Therapeutics | Biopharmaceuticals | $150M | n/m | |
| Werewolf Therapeutics | Ambros Therapeutics | Biopharmaceuticals | $550M | n/m | |
| Kartos Therapeutics | Ipsen | Biopharmaceuticals | $520M – $700M | n/m | |
| Kashiv BioSciences, LLC | Amneal Pharmaceuticals, Inc. | Biopharmaceuticals | $150M – $200M | 7× – 9× | |
| Lōkahi Therapeutics | Glucotrack, Inc. | Biopharmaceuticals | $26.0M – $35.0M | n/m | |
| Indivior Pharmaceuticals, Inc. | Supernus Pharmaceuticals Inc. | Biopharmaceuticals | $1,000M | 2.5× | |
| Attovia Therapeutics | Undisclosed | Biopharmaceuticals | $289M | n/m | |
| Metsera | Pfizer | Biopharmaceuticals | $10,000M | n/m | |
| Crinetics Pharmaceuticals | Vertex Pharmaceuticals Incorporated | Biopharmaceuticals | $10,000M | n/m | |
| AstraZeneca and Bristol Myers Squibb | AstraZeneca, Bristol Myers Squibb | Biopharmaceuticals | $400,000M | 5× – 7× |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.